{
    "nct_id": "NCT04733534",
    "official_title": "SEN-SURVIVORS: An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer",
    "inclusion_criteria": "* Participant in SJLIFE and > 5 years from diagnosis.\n* ≥18 years of age.\n* Frail (2 of 4 objectively measured Fried criteria adapted,(excluding self-reported fatigue as a criteria), including abnormal walking speed; muscle strength; activity level; and muscle mass). See Section 5 for details.\n* CD3+ T lymphocytes: p16INK4A detected at <34 cycles by RT PCR.\n* Agrees to use contraception as Dasatinib is teratogenic.\n* Female participant has a negative pregnancy test.\n* QTc <450 milliseconds in electrocardiogram.\n* Able to take oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently has HIV, Hepatitis B/C, invasive fungal infection\n* Anemia or as per clinical judgement.\n* Hypersensitivity to study drugs\n* New/active malignancy/taking chemotherapy and/or radiation except non-melanoma skin cancers\n* Currently taking medications that inhibit or induce CYP3A4 or that are sensitive to substrates or substrates with a narrow therapeutic range for CYP2C8, CYP2C9, or CYP2D6.\n* Taking anticoagulants or antimicrobial agents\n* Currently taking Quercetin or Fisetin\n* Pregnant or nursing at time of enrollment/during the study\n* Impaired cognition or motor performance due to congenital defects\n* Currently participating in another research intervention to aid walking speed or other measures of frailty including muscle strength; low activity; muscle mass or exhaustion/fatigue\n* Participant is a Non-English Speaker\n* Uncontrolled pleural/pericardial effusion or ascites\n* Subjects on anticoagulant or antiplatelet agents (Warfarin, Clopidogrel [Plavix]; Dipyridamole + Aspirin [Aggrenox]; Ticagrelor [Brilintal]; Prasugrel [Effient]; Ticlopidine [Ticlid]; or other) who are unable or unwilling to reduce or hold therapy prior to and during the 2-3 day drug dosing. Subjects may continue their previous regimen after drug dosing is complete.\n* Cognitive impairment defined by IQ <80\n* Diagnosis of a psychotic disorder\n* Laboratory tests as indicated or as per clinical judgement\n* Severe hepatic dysfunction with ALT/AST > 3 times upper limit of normal.\n* Total bilirubin > 2 times upper limit of normal.\n* eGFR <25 ml/min/1.73m2 or as per clinical judgement.\n* Hemoglobin < 7 g/dl; white blood cell count ≤2,000/mm3 (≤2.0 x 109/L) or ≥20,000/mm3 (≥20 x 109/L); platelet count ≤40,000/μL (≤40 x 109/L); absolute neutrophil count ≤1 x 109/L; lymphocyte count <0.3 x 109/L at screening as a marker of poor nutrition\n* Fasting glucose >300.\n* Participant is unable to ambulate",
    "miscellaneous_criteria": ""
}